Message from Serge Weinberg, Chairman of the Board of Directors
The second quarter 2017 was marked by the launch of our Immunology franchise with the approval of Kevzara® in moderate to severe adult rheumatoid arthritis in the United States and the European Union, and Dupixent®, a revolutionary treatment for atopic dermatitis, in the United States. These important achievements demonstrate the robustness of Sanofi's portfolio...
Interview with Olivier Brandicourt, CEO
How would you assess the second quarter of 2017?
I’m satisfied with our results in the second quarter and beyond, with the better than expected financial performance in the first half of the year...
Can you tell us more about the performance of Sanofi Genzyme, Sanofi Pasteur and Emerging Markets?
Sanofi Genzyme's Specialty Care franchise was up 13.6% , with growth in all businesses across both developed and emerging markets...
What about progress in Research & Development?
I would like to highlight the following major developments. Dupilumab entered phase 3 in adolescent atopic dermatitis and pediatric asthma...
Second quarter 2017 results
Sales supported by Specialty Care and Vaccines
Net sales were €8,663M in the second quarter of 2017, an increase of 6.4% on a reported basis and 5.5% at CER, reflecting the change in scope of the Global Business Units Consumer Healthcare (acquisition of Boehringer Ingelheim's Consumer Healthcare business and the disposal of the Animal Health business) and Vaccines (consolidation of Sanofi's vaccine business in Europe).
Kevzara® approved in Europe
At the end of June 2017, the European Commission granted marketing authorization to Kevzara® (sarilumab) in combination with methotrexate for the treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately or who are intolerant to one or more disease modifying anti-rheumatic drugs, such as methotrexate. Rheumatoid arthritis affects approximately 2.9 million people in Europe.
Dupilumab: new clinical data and regulatory milestones
- Positive opinion for marketing authorization of Dupixent® (dupilumab) in Europe
- New positive phase 3 study results for Dupixent® in patients with moderate-to-severe atopic dermatitis
- Positive dupilumab topline results from phase 3 trial in uncontrolled persistent asthma
- Cemiplimab receives breakthrough therapy designation for advanced cutaneous squamous cell carcinoma
- Approval in Europe of Insulin lispro Sanofi®
- Collaboration with Ablynx
- Sanofi rated AA by Scope Ratings
Acquisition of Protein Sciences
A key acquisition for Sanofi Pasteur
On August 28, 2017, Sanofi completed the acquisition of Protein Sciences, a U.S. vaccines biotechnology company. This acquisition will help strengthen our leadership position in the influenza vaccines market. Sanofi Pasteur is the world’s largest manufacturer of influenza vaccines.
Visit to Ambarès production site by the Shareholders Committee
On June 28, 2017, the Individual Shareholders Committee visited Sanofi’s Ambarès production site, near Bordeaux, France. Ambarès is a major manufacturing and packaging facility specialized in two types of production: dry formulas (tablets, coated tablets, capsules) and injectables in the form of ampoules. The site manufactures some of Sanofi’s key products...
Salon Actionaria 2017
Save the date for Salon Actionaria 2017
The Sanofi Investor Relations team will be happy to welcome you at the 20th edition of Actionaria, Europe’s largest exhibition for individual shareholders, on November 23 & 24, 2017 Palais des Congrès de Paris 2, Place de la Porte Maillot - 75017 Paris. Come and join us at Espace “Grandes Cap”, Level 2 - stand E 78, from 1:00 pm to 10:00 pm CET on Thursday and from 9:30 am to 7:00 pm CET on Friday.
Upcoming shareholder meetings in France
In the second half of the year, we will come to meet you at three additional meetings:
- September 19, 2017: Strasbourg
- October 2, 2017: Lyon
- December 14, 2017: Rouen